- Home
- / Oyster Point Pharma
Oyster Point Pharma
Stock Price
$11.2
2023-01-11
Market Capitalization
$292.3 M
2023-01-11
Revenue
$24.5 M
FY, 2021
Oyster Point Pharma Summary
Company Summary
- Overview
- Oyster Point Pharma is a clinical-stage pharmaceutical company. The company focuses on the discovery, development, and commercialization of novel therapies to treat ocular surface disease.
- Type
- Public
- Status
- Active
- Founded
- 2015
- HQ
- Princeton, NJ, US | view all locations
- Website
- https://oysterpointrx.com
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
George Donato, Senior Vice President, CMC and Operations
Eric Carlson, Chief Scientific Officer
Marian Macsai, Chief Medical Officer
LocationsView all
1 location detected
Princeton, NJ HQ
United States
202 Carnegie Center Dr #109
Oyster Point Pharma Financials
Summary Financials
- Revenue (Q3, 2022)
- $5.6M
- Gross profit (Q3, 2022)
- $4.2M
- Net income (Q3, 2022)
- ($36.7M)
- Cash (Q3, 2022)
- $68.8M
- EBIT (Q3, 2022)
- ($33.9M)
- Enterprise value
- $316.3M